CIP2A expression is elevated in cervical cancer

Cancer Biomarkers

Volumn 8, Issue 6, 2010, Pages 309-317

  Huang, Lisa P ^a   Adelson, Martin E ^a   Mordechai, Eli ^a   Trama, Jason P ^a  

^a Medical Diagnostic Laboratories LLC   (United States)

Author keywords

cancer biomarker; cancer diagnostic; Cervical cancer; CIP2A; p16 INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN CIP2A; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WESTERN BLOTTING;

ADULT; AGED; AUTOANTIGENS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HL-60 CELLS; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 80955160006     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0220     Document Type: Article

References (47)

1. J. Abu, M. Batuwangala and P. Symonds, Expression of RAR beta2 gene by real-time RT-PCR: differential expression in normal subjects compared to cervical cancer patients normalised against GAPDH as a housekeeping gene, Eur J Obstet Gynecol Reprod Biol 140 (2008), 295-296.
2. M. Arbyn, G. Ronco, J. Cuzick, N.Wentzensen and P.E. Castle, How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 125 (2009), 2489-2496.
3. A. Balasubramanian, J. Hughes, C. Mao et al., Evaluation of an ELISA for p16INK4a as a screening test for cervical cancer, Cancer Epidemiol Biomarkers Prev 18 (2009), 3008-3017.
4. P. Baldwin, R. Laskey and N. Coleman, Translational approaches to improving cervical screening, Nat Rev Cancer 3 (2003), 217-226. (Pubitemid 37328873)
5. J.R. Basile and R. Czerninski, The role of CIP2A in oral squamous cell carcinoma, Cancer Biol Ther 10, 700-702.
6. G.A. Boulet, C.A. Horvath, C.E. Depuydt and J.J. Bogers, Biomarkers in cervical screening: quantitative reverse transcriptase PCR analysis of P16INK4a expression, Eur J Cancer Prev 19, 35-41.
7. L.M. Boxer and C.V. Dang, Translocations involving c-myc and c-myc function, Oncogene 20 (2001), 5595-5610. (Pubitemid 32928100)
8. H.B. Cai, C.C. Chen and X.H. Ding, Human papillomavirus type 16 E6 gene variations in Chinese population, Eur J Surg Oncol 36, 160-163.
9. K.F. Chen, C.Y. Liu, Y.C. Lin et al., CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells, Oncogene 29, 6257-6266.
10. E.A. Coenen, C.M. Zwaan, C. Meyer et al., KIAA1524: A novel MLL translocation partner in acute myeloid leukemia, Leuk Res 35, 133-135.
11. C. Come, A. Laine, M. Chanrion et al., CIP2A is associated with human breast cancer aggressivity, Clin Cancer Res 15 (2009), 5092-5100.
12. I.I. Daud and M.E. Scott, Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays, Clin Vaccine Immunol 15 (2008), 1369-1373.
13. D. Dehn, K.C. Torkko and K.R. Shroyer, Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma, Cancer 111 (2007), 1-14. (Pubitemid 46281079)
14. R.M. DeMay, Cytopathology of false negatives preceding cervical carcinoma, AmJObstetGynecol 175 (1996), 1110-1113. (Pubitemid 26357927)
15. Q.Z. Dong,Y.Wang, X.J. Dong et al., CIP2A isOverexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis, Ann Surg Oncol.
16. R. Gavioli, T. Frisan, S. Vertuani, G.W. Bornkamm and M.G. Masucci, c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells, Nat Cell Biol 3 (2001), 283-288. (Pubitemid 32203678)
17. N. Grabe, B. Lahrmann, T. Pommerencke, M. von Knebel Doeberitz, M. Reuschenbach and N. Wentzensen, A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides, Cell Oncol 32, 109-119.
18. M. Hampl, N. Wentzensen, S. Vinokurova et al., Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile, J Cancer Res Clin Oncol 133 (2007), 235-245.
19. M.R. Junttila, P. Puustinen, M. Niemela et al., CIP2A inhibits PP2A in human malignancies, Cell Cycle 130 (2007), 51-62. (Pubitemid 47039258)
20. M.R. Junttila and J. Westermarck, Mechanisms of c-MYC stabilization in humanmalignancies, Cell Cycle 7 (2008), 592-596.
21. A. Kamb, N.A. Gruis, J. Weaver-Feldhaus et al., A cell cycle regulator potentially involved in genesis of many tumor types, Science 264 (1994), 436-440.
22. J. Katz, A. Jakymiw, M.K. Ducksworth et al., CIP2A expression and localization in oral carcinoma and dysplasia, Cancer Biol Ther 10, 694-699.
23. L. Kerosuo, H. Fox, N. Perala et al., CIP2A increases selfrenewal and is linked to Myc in neural progenitor cells, Differentiation 80, 68-77.
24. A. Khanna, C.Bockelman, A.Hemmes et al.,MYC-dependent regulation and prognostic role of CIP2A in gastric cancer, J Natl Cancer Inst 101 (2009), 793-805.
25. S.N. Khleif, J. DeGregori, C.L. Yee et al., Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity, Proc Natl Acad Sci U S A 93 (1996), 4350-4354.
26. W. Li, Z. Ge, C. Liu et al., CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells, Clin Cancer Res 14 (2008), 3722-3728.
27. K.Matsumoto, T. Yasugi, S. Nakagawa et al., Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanesewomenwith cervical cancer, Int J Cancer 106 (2003), 919-922. (Pubitemid 37071671)
28. N. Murphy, C.C. Heffron, B. King et al., p16INK4a positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem, Virchows Arch 445 (2004), 610-615. (Pubitemid 40104536)
29. N. Murphy, M. Ring, C.C. Heffron et al., p16INK4a, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer, J Clin Pathol 58 (2005), 525-534. (Pubitemid 40646875)
30. K. Nanda, D.C. McCrory, E.R. Myers et al., Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review, Ann Intern Med 132 (2000), 810-819. (Pubitemid 30317797)
31. M.L. Nguyen, R.M. Kraft and J.A. Blaho, Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis, J Gen Virol, 88 (2007), 1866-1875. (Pubitemid 47009927)
32. W. Qu, W. Li, L. Wei, L. Xing, X. Wang and J. Yu, CIP2A is overexpressed in esophageal squamous cell carcinoma, Med Oncol.
33. A.D. Santin, F. Zhan, E. Bignotti et al., Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy, Virology 331 (2005), 269-291. (Pubitemid 40075455)
34. K. Shchors, E. Shchors, F. Rostker, E.R. Lawlor, L. Brown- Swigart and G.I. Evan, TheMyc-dependent angiogenic switch in tumors is mediated by interleukin 1beta, Genes Dev 20 (2006), 2527-2538. (Pubitemid 44396838)
35. C.J. Sherr, Cancer cell cycles, Science 274 (1996), 1672-1677.
36. F.D. Shi, J.Y. Zhang, D. Liu et al., Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens, Prostate 63 (2005), 252-258. (Pubitemid 40571059)
37. L. Soo Hoo, J.Y. Zhang and E.K. Chan, Cloning and characterization of a novel 90 kDa cacute;ompanion' auto-antigen of p62 overexpressed in cancer, Oncogene 21 (2002), 5006-5015.
38. M.H. Stoler, Testing for human papillomavirus: data driven implications for cervical neoplasiamanagement, Clin LabMed 23 (2003), 569-583. (Pubitemid 37175545)
39. M.H. Vaarala, M.R. Vaisanen and A. Ristimaki, CIP2A expression is increased in prostate cancer, J Exp Clin Cancer Res 29, 136.
40. J. Vervoorts, J. Luscher-Firzlaff and B. Luscher, The ins and outs of MYC regulation by posttranslational mechanisms, J Biol Chem 281 (2006), 34725-34729. (Pubitemid 46036511)
41. M. Vita and M. Henriksson, The Myc oncoprotein as a therapeutic target for human cancer, Semin Cancer Biol 16 (2006), 318-330. (Pubitemid 44311040)
42. J. Wang, W. Li, L. Li, X. Yu, J. Jia and C. Chen, CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation, Int J Lab Hematol.
43. N. Wentzensen, M. Hampl, M. Herkert et al. Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples, Cancer 107 (2006), 2307-2313. (Pubitemid 44665667)
44. T.C.Wright, Jr., Cervical cancer screening in the 21st century: Is it time to retire the PAP smear? Clin Obstet Gynecol 50 (2007), 313-323. (Pubitemid 46869783)
45. E. Yeh, M. Cunningham, H. Arnold et al., A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells, Nat Cell Biol 6 (2004), 308-318. (Pubitemid 38584820)
46. I. Zehbe, C. Richard, C.A. DeCarlo et al., Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis, Virology 383 (2009), 69-77.
47. D. Zhao, Z. Liu, J. Ding et al., Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src andMEK/ERK pathways, J Med Microbiol 59, 259-265.